Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Aligos Therapeutics, Inc. (ALGS)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19
   10-K10-K10-K10-K
Revenues  0.00.00.055.9
            Revenue growth    -100.0% 
Cost of goods sold  0.00.00.00.0
Gross profit  0.00.00.055.9
            Gross margin     100.0%
Selling, general and administrative   [+]111.5132.797.810.0
Research and development     44.0
Other operating expenses   -132.79.855.9
EBITDA   [+]   -52.6
            EBITDA margin     -94.2%
Depreciation and amortization     1.4
EBIT   [+]-111.50.0-107.6-54.0
            EBIT margin     -96.7%
Other income (expense), net  15.5-128.2-0.81.9
Pre-tax income  -95.9-128.2-108.4-52.2
Income taxes  0.10.10.20.1
Net income  -96.0-128.3-108.5-52.3
            Net margin     -93.5%
   
Basic EPS   [+]($2.25)($3.22)($10.87)($26.04)
Diluted EPS   [+]($2.25)($3.22)($10.87)($26.04)
   
Shares outstanding (basic)   [+]42.739.910.02.0
Shares outstanding (diluted)   [+]42.739.910.02.0
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy